Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease
Author / Expert
Alex L. Huang, Emily M. Scire, Tanya Dang, Melody Tai, Eva Zacharakis, Blen Yohannes, Ina Kycia, David Zurakowski, Dario O. Fauza
Topic overview
Modified monoclonal class-G immunoglobulins (IgG) have been shown to protect infants from respiratory syncytial virus (RSV), a prevalent disease with particularly high morbidity in newborns. We sought to determine whether a clinically relevant monoclonal IgG against RSV could be delivered to the fetus via transammiotic fetal immunotherapy (TRAFIT) and remain bioavailable after birth.
Comments